TherapeuticsMD Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Marlan Walker
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 46.7% |
| CEO tenure | 2yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
TherapeuticsMD raises $7M in private placement
Oct 03TherapeuticsMD appoints interim co-CEOs
Sep 12Therapeutics MD Q2 Earnings Preview
Aug 12TherapeuticsMD receives $15M equity investment from Rubric Capital
Aug 01TherapeuticsMD jumps 12% as top investor discloses insider purchase
Jul 19TherapeuticsMD plunges 42% as merger agreement ends
Jul 13TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition
Jul 06TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback
Jun 16TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business
Mar 14TherapeuticsMD: Time For Bulls To Take A Contrarian Approach
Oct 22TherapeuticsMD: The Long Road To Profitability
Jul 08TherapeuticsMD drops 3% despite consensus beating Q1 results
May 06TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?
Feb 24
TherapeuticsMD: Annovera May Save The Day
Feb 04TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be
Jan 29What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?
Jan 27Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?
Dec 30
TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years
Dec 09TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook
Nov 25Therapeutics MD EPS beats by $0.01, beats on revenue
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | US$1m | US$476k | -US$8m |
| Sep 30 2023 | n/a | n/a | US$42m |
| Jun 30 2023 | n/a | n/a | US$29m |
| Mar 31 2023 | n/a | n/a | US$17m |
| Dec 31 2022 | US$2m | US$425k | US$1m |
| Sep 30 2022 | n/a | n/a | US$3m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$58m |
| Dec 31 2021 | US$2m | US$415k | -US$79m |
Compensation vs Market: Marlan's total compensation ($USD1.02M) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Marlan's compensation has been consistent with company performance over the past year.
CEO
Marlan Walker (49 yo)
2yrs
Tenure
US$1,019,817
Compensation
Mr. Marlan D. Walker, J.D., has been Chief Executive Officer of TherapeuticsMD, Inc since December 2022 and was its General Counsel since March 2016 until 2023. He served as the Secretary of TherapeuticsMD...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 12.6yrs | US$193.75k | 0.18% $ 22.5k | |
| Chief Executive Officer | 2yrs | US$1.02m | 0.54% $ 69.4k | |
| Principal Financial & Accounting Officer | 1.3yrs | US$172.62k | 0% $ 0 | |
| Vice President of Market Access | no data | no data | no data |
2.0yrs
Average Tenure
50yo
Average Age
Experienced Management: TXMD's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 12.6yrs | US$193.75k | 0.18% $ 22.5k | |
| Independent Director | 4.8yrs | US$111.25k | 0% $ 0 | |
| Independent Director | 12.8yrs | US$133.25k | 0.45% $ 57.7k | |
| Independent Director | 2.3yrs | no data | no data |
8.7yrs
Average Tenure
56.5yo
Average Age
Experienced Board: TXMD's board of directors are considered experienced (8.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 16:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TherapeuticsMD, Inc. is covered by 18 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Tanner | Cantor Fitzgerald & Co. |
| Robert Labick | CJS Securities, Inc. |
| Esther Rajavelu | Deutsche Bank |